Ocera Therapeutics Inc (NASDAQ:OCRX) is a company with one main value driver, OCR002. Financially, the company is now sitting on $47.2 M and will be spending $30M in the 2014 financial year. It has about one year in cash. Last year, it spent $3.5M in R&D and these costs are set to increase as it ramps up the Phase 2 trials for OCR002. Ocera Therapeutics Inc (NASDAQ:OCRX) stock performance was -8.82% in last session and finished the day at $10.55. Traded volume was 221,385.00million shares in the last session and the average volume of the stock remained 99.95K shares. Ocera Therapeutics Inc (NASDAQ:OCRX) insider ownership is 49.71%.

Marina Biotech, Inc. (OTCMKTS:MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that it plans to broadly apply its RNAi, antisense and microRNA therapeutics platform to develop drugs for rare diseases. Marina Biotech, Inc. (OTCMKTS:MRNA) dropped -17.59 percent to $0.890 Monday on volume of 275,685.00million shares. The intra-day range of the stock was $0.86 to $1.09. Marina Biotech, Inc. (OTCMKTS:MRNA) has a market capitalization of $15.07million.

CorMedix Inc. (NYSEMKT:CRMD), a specialty pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of infectious diseases in both acute and chronic care settings, today announced that it will report 2013 financial results on Monday, March 31, 2014. The Company’s Chief Executive Officer, Randy Milby, will be hosting a conference call on Tuesday, April 1, 2014 at 9:00 a.m. ET to discuss the Company’s 2013 results. CorMedix Inc. (NYSEMKT:CRMD)’s stock on Mar 31, 2014 reported a decrease of -5.64% to the closing price of $2.51. Its fifty two weeks range is $0.48 -$3.20. The total market capitalization recorded $54.95million. The overall volume in the last trading session was 198,938.00million shares. In its share capital, CRMD has 21.88million outstanding shares.

TheStreet has also updated their ratings on a number of other healthcare stocks in the last week. The firm downgraded shares of Idera Pharmaceuticals Inc (NASDAQ:IDRA) from a hold rating to a sell rating. On Monday, shares of Idera Pharmaceuticals Inc (NASDAQ:IDRA) dropped -10.72% to close the day at $4.08. Company monthly performance is recorded as -29.53%. Idera Pharmaceuticals Inc (NASDAQ:IDRA) quarterly revenue growth is 20.00%.